{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:15:39Z","timestamp":1784034939662,"version":"3.55.0"},"reference-count":81,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,1,23]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To clarify the risk of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) related to anti-cyclic citrullinated peptide (CCP) antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Patients with RA with and without ILD were eligible. The primary outcome was the prevalence or incidence of ILD. Primary studies of any design aside from a case report were eligible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Information sources<\/jats:title>\n                    <jats:p>Medline, EMBASE, Science Citation Index Expanded and Cochrane Central Register of Controlled Trials were searched from the inception through 12 November 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and risk of bias<\/jats:title>\n                    <jats:p>Two reviewers independently selected eligible reports, extracted relevant data and assessed risk of bias using a modified Quality in Prognostic Studies tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis<\/jats:title>\n                    <jats:p>Meta-analysis was conducted using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Quality of evidence<\/jats:title>\n                    <jats:p>The Grades of Recommendation, Assessment, Development and Evaluation system was applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 29 out of 827 records retrieved through electronic databases and four additional reports identified from other sources, 29 studies were focused for the review. A total of 10158 subjects were included and the mean age at inclusion was between 45.8 and 63.9 years. The mean RA duration was between 4.3 and 14.9 years. The positivity of anti-CCP antibody ranged from 50.7% to 95.8%. All studies except for two were deemed as high risk of bias. A pooled analysis of univariate results demonstrated that the presence of anti-CCP antibody was significantly associated with RA-ILD with an OR of 2.10 (95% CI: 1.59 to 2.78). Similarly, the titre of anti-CCP antibody was significantly higher for RA-ILD with a standardised mean difference of 0.42 (95% CI: 0.20 to 0.65). These results were confirmed by multivariate analysis in the majority of studies and consistent by any subgroup and sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The presence and higher titres of anti-CCP antibody were suggested to be significantly associated with an increased risk of RA-ILD. However, the quality of evidence was rated as low or very low.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-040465","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T12:29:07Z","timestamp":1617193747000},"page":"e040465","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-1279","authenticated-orcid":false,"given":"Hiroyuki","family":"Kamiya","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tatebayashi Kosei Hospital, Tatebayashi, Gunma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogee Mer","family":"Panlaqui","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Northern Hospital, Epping, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"2025121600051442000_11.3.e040465.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8. PubMed PMID: 27156434."},{"key":"2025121600051442000_11.3.e040465.2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835f693f"},{"key":"2025121600051442000_11.3.e040465.3","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00008014"},{"key":"2025121600051442000_11.3.e040465.4","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X15612250"},{"key":"2025121600051442000_11.3.e040465.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003132"},{"key":"2025121600051442000_11.3.e040465.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-016-0269-2","article-title":"Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes","volume":"16","author":"Nurmi","year":"2016","journal-title":"BMC Pulm Med"},{"key":"2025121600051442000_11.3.e040465.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.7.668"},{"key":"2025121600051442000_11.3.e040465.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.27405"},{"key":"2025121600051442000_11.3.e040465.9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00019210"},{"key":"2025121600051442000_11.3.e040465.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.05.002"},{"key":"2025121600051442000_11.3.e040465.11","first-page":"235","article-title":"Practical approach to the evaluation and management of rheumatoid arthritis-interstitial lung disease based on its proven and hypothetical mechanisms","volume":"69","author":"Paulin","year":"2017","journal-title":"Rev Invest Clin"},{"key":"2025121600051442000_11.3.e040465.12","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.2.9609016"},{"key":"2025121600051442000_11.3.e040465.13","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.59"},{"key":"2025121600051442000_11.3.e040465.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1492-5"},{"key":"2025121600051442000_11.3.e040465.15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3561-5"},{"key":"2025121600051442000_11.3.e040465.16","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"2010","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025121600051442000_11.3.e040465.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101261"},{"key":"2025121600051442000_11.3.e040465.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2008.06.014"},{"key":"2025121600051442000_11.3.e040465.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111478"},{"key":"2025121600051442000_11.3.e040465.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131341"},{"key":"2025121600051442000_11.3.e040465.21","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"2025121600051442000_11.3.e040465.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"2025121600051442000_11.3.e040465.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2025121600051442000_11.3.e040465.24","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.2.ats01"},{"key":"2025121600051442000_11.3.e040465.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2025121600051442000_11.3.e040465.26","doi-asserted-by":"publisher","DOI":"10.1080\/03009740310003677"},{"key":"2025121600051442000_11.3.e040465.27","first-page":"CD000957","article-title":"Methotrexate for treating rheumatoid arthritis","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121600051442000_11.3.e040465.28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138237"},{"key":"2025121600051442000_11.3.e040465.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020862"},{"key":"2025121600051442000_11.3.e040465.30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-6-200603210-00010"},{"key":"2025121600051442000_11.3.e040465.31","doi-asserted-by":"publisher","DOI":"10.3102\/10769986006002107"},{"key":"2025121600051442000_11.3.e040465.32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135"},{"key":"2025121600051442000_11.3.e040465.33","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2025121600051442000_11.3.e040465.34","unstructured":"Higgins JPT , Green S . Cochrane Handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration 2011"},{"key":"2025121600051442000_11.3.e040465.35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d549"},{"key":"2025121600051442000_11.3.e040465.36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025121600051442000_11.3.e040465.37","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-2-71"},{"key":"2025121600051442000_11.3.e040465.38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex520"},{"key":"2025121600051442000_11.3.e040465.39","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/art.40900","article-title":"Malondialdehyde-acetaldehyde adducts and antibody responses in rheumatoid arthritis-associated interstitial lung disease","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025121600051442000_11.3.e040465.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203160"},{"key":"2025121600051442000_11.3.e040465.41","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/569751"},{"key":"2025121600051442000_11.3.e040465.42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.38904","article-title":"Biomarkers of rheumatoid arthritis-associated interstitial lung disease","volume":"67","author":"Chen","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025121600051442000_11.3.e040465.43","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201411-1950OC"},{"key":"2025121600051442000_11.3.e040465.44","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.21608\/ejhm.2019.39163","article-title":"Increased risk of rheumatoid arthritis-related pulmonary disease as a results of serum anticitrullinated protein antibody positivity","volume":"76","author":"Abdel-Mageed","year":"2019","journal-title":"Egypt J Hosp Med"},{"key":"2025121600051442000_11.3.e040465.45","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00296-016-3478-3","article-title":"Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study","volume":"36","author":"Akiyama","year":"2016","journal-title":"Rheumatol Int"},{"key":"2025121600051442000_11.3.e040465.46","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0800-1"},{"key":"2025121600051442000_11.3.e040465.47","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10067-018-04421-0","article-title":"Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease","volume":"38","author":"Correia","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025121600051442000_11.3.e040465.48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejr.2017.10.006","article-title":"Interstitial lung disease in Egyptian patients with rheumatoid arthritis: frequency, pattern and correlation with clinical manifestations and anti-citrullinated peptide antibodies level","volume":"40","author":"Fadda","year":"2018","journal-title":"The Egyptian Rheumatologist"},{"key":"2025121600051442000_11.3.e040465.49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033133"},{"key":"2025121600051442000_11.3.e040465.50","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/14397595.2019.1621462","article-title":"Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"30","author":"Kakutani","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2025121600051442000_11.3.e040465.51","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu165"},{"key":"2025121600051442000_11.3.e040465.52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clim.2019.01.001","article-title":"High levels of antibodies to citrullinated \u03b1-enolase peptide-1 (CEP-1) identify erosions and interstitial lung disease (ILD) in a Chinese rheumatoid arthritis cohort","volume":"200","author":"Liu","year":"2019","journal-title":"Clin Immunol"},{"key":"2025121600051442000_11.3.e040465.53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/03009742.2018.1477989","article-title":"Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study","volume":"48","author":"Matsuo","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"2025121600051442000_11.3.e040465.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.07.006"},{"key":"2025121600051442000_11.3.e040465.55","first-page":"193","article-title":"Anti-Cyclic citrullinated peptide antibodies in rheumatoid arthritis and their relationship with extra-articular manifestations","volume":"26","author":"Ortanc\u0131l","year":"2011","journal-title":"Turk J Rheumatol"},{"key":"2025121600051442000_11.3.e040465.56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00408-015-9828-1","article-title":"Visual assessment of chest computed tomography findings in anti-cyclic citrullinated peptide antibody positive rheumatoid arthritis: is it associated with airway abnormalities?","volume":"194","author":"Park","year":"2016","journal-title":"Lung"},{"key":"2025121600051442000_11.3.e040465.57","first-page":"30111","article-title":"Development of a risk indicator score for the identification of interstitial lung disease in patients with rheumatoid arthritis","author":"Paulin","year":"2019","journal-title":"Reumatol Clin"},{"key":"2025121600051442000_11.3.e040465.58","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-3025-8"},{"key":"2025121600051442000_11.3.e040465.59","first-page":"1","article-title":"Anti-cyclic citrullinated peptide antibodies and severity of interstitial lung disease in women with rheumatoid arthritis","volume":"2015","author":"Rocha-Mu\u00f1oz","year":"2015","journal-title":"J Immunol Res"},{"key":"2025121600051442000_11.3.e040465.60","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5606\/ArchRheumatol.2018.6691","article-title":"Tumor-associated antigens in rheumatoid arthritis interstitial lung disease or malignancy?","volume":"33","author":"Sargin","year":"2018","journal-title":"Arch Rheumatol"},{"key":"2025121600051442000_11.3.e040465.61","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014945","article-title":"Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients","volume":"98","author":"Sulaiman","year":"2019","journal-title":"Medicine"},{"key":"2025121600051442000_11.3.e040465.62","first-page":"6813","article-title":"The anti-mutated citrullinated vimentin antibody as a potential predictor for rheumatoid arthritis associated interstitial lung diseases","volume":"9","author":"Tian","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"2025121600051442000_11.3.e040465.63","doi-asserted-by":"crossref","DOI":"10.1038\/srep14897","article-title":"Clinical features of rheumatoid arthritis-associated interstitial lung disease","volume":"5","author":"Wang","year":"2015","journal-title":"Sci Rep"},{"key":"2025121600051442000_11.3.e040465.64","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3904\/kjim.2016.349","article-title":"Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis","volume":"34","author":"Yang","year":"2019","journal-title":"Korean J Intern Med"},{"key":"2025121600051442000_11.3.e040465.65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092449"},{"key":"2025121600051442000_11.3.e040465.66","first-page":"46","article-title":"Changes and clinical significance of serum tumor markers in patients with rheumatoid arthritis combined with interstitial lung disease","volume":"24","author":"Zhang","year":"2018","journal-title":"J Hainan Med Univ"},{"key":"2025121600051442000_11.3.e040465.67","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092309"},{"key":"2025121600051442000_11.3.e040465.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.05.007"},{"key":"2025121600051442000_11.3.e040465.69","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/815038"},{"key":"2025121600051442000_11.3.e040465.70","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4049\/jimmunol.162.1.585","article-title":"The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues","volume":"162","author":"Girbal-Neuhauser","year":"1999","journal-title":"J Immunol"},{"key":"2025121600051442000_11.3.e040465.71","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3"},{"key":"2025121600051442000_11.3.e040465.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.09.015"},{"key":"2025121600051442000_11.3.e040465.73","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054445"},{"key":"2025121600051442000_11.3.e040465.74","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535790"},{"key":"2025121600051442000_11.3.e040465.75","doi-asserted-by":"publisher","DOI":"10.1038\/ng.480"},{"key":"2025121600051442000_11.3.e040465.76","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000946"},{"key":"2025121600051442000_11.3.e040465.77","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"2025121600051442000_11.3.e040465.78","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu195"},{"key":"2025121600051442000_11.3.e040465.79","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/759760","article-title":"The multifaceted aspects of interstitial lung disease in rheumatoid arthritis","volume":"2013","author":"Cavagna","year":"2013","journal-title":"Biomed Res Int"},{"key":"2025121600051442000_11.3.e040465.80","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-017-0701-5","article-title":"Rheumatoid arthritis-associated interstitial lung disease: current concepts","volume":"19","author":"Brito","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"2025121600051442000_11.3.e040465.81","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212365"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-040465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:05:25Z","timestamp":1765872325000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-040465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,31]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/bmjopen-2020-040465"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-040465","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}